INM-089 / InMed Pharma - LARVOL DELTA

INM-089 Program Outlook (Investing News Network (INN)) - "Generation of data supporting continued evaluation of therapeutic potential; Completion of preclinical studies, including dose-ranging assessment, demonstrating dose proportionality and pharmacologically relevant concentration following dosing; Drug substance and drug product process in place to support IND enabling studies, with further optimization expected in advance of IND submission; Planning for a pre-IND meeting with the FDA in Q4 2026."

FDA event • Preclinical • Dry Age-related Macular Degeneration